Literature DB >> 18474552

Safety and immunogenicity of myxoma virus as a new viral vector for small ruminants.

Béatrice Pignolet1,2, Séverine Boullier1,2, Jacqueline Gelfi1,2, Marjorie Bozzetti1,2, Pierre Russo3, Eliane Foulon1,2, Gilles Meyer1,2, Maxence Delverdier1,2, Gilles Foucras1,2, Stéphane Bertagnoli1,2.   

Abstract

Myxoma virus (MYXV), a leporide-specific poxvirus, represents an attractive candidate for the generation of safe and non-replicative vaccine vectors for other species. With the aim of developing new recombinant vaccines for ruminants, we evaluated the safety and the immunogenicity of recombinant MYXV in sheep. In vitro studies indicated that ovine primary fibroblasts were not permissive for MYXV and that infection of ovine peripheral blood mononuclear cells occurred at a low rate. Although non-specific activation significantly improved the susceptibility of lymphocytes, MYXV infection remained abortive. Histological and immunohistochemical examination at the inoculation sites revealed the development of an inflammatory process and allowed the detection of sparse infected cells in the dermis. In addition, inoculated sheep developed an antibody response directed against MYXV and the product of the transgene. Overall, these results provide the first line of evidence on the potential of MYXV as a viral vector for ruminants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474552     DOI: 10.1099/vir.0.83595-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Infection of nonhost species dendritic cells in vitro with an attenuated myxoma virus induces gene expression that predicts its efficacy as a vaccine vector.

Authors:  S Top; E Foulon; B Pignolet; M Deplanche; C Caubet; C Tasca; S Bertagnoli; G Meyer; G Foucras
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.

Authors:  Rosalinda A Doty; Jia Liu; Grant McFadden; Edward J Roy; Amy L MacNeill
Journal:  Oncolytic Virother       Date:  2013-01

3.  Expression of VP7, a Bluetongue virus group specific antigen by viral vectors: analysis of the induced immune responses and evaluation of protective potential in sheep.

Authors:  Coraline Bouet-Cararo; Vanessa Contreras; Agathe Caruso; Sokunthea Top; Marion Szelechowski; Corinne Bergeron; Cyril Viarouge; Alexandra Desprat; Anthony Relmy; Jean-Michel Guibert; Eric Dubois; Richard Thiery; Emmanuel Bréard; Stephane Bertagnoli; Jennifer Richardson; Gilles Foucras; Gilles Meyer; Isabelle Schwartz-Cornil; Stephan Zientara; Bernard Klonjkowski
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

4.  Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma.

Authors:  Amy L MacNeill; Kristen M Weishaar; Bernard Séguin; Barbara E Powers
Journal:  Viruses       Date:  2018-07-28       Impact factor: 5.048

Review 5.  Viral Vector Vaccines against Bluetongue Virus.

Authors:  Luis Jiménez-Cabello; Sergio Utrilla-Trigo; Eva Calvo-Pinilla; Sandra Moreno; Aitor Nogales; Javier Ortego; Alejandro Marín-López
Journal:  Microorganisms       Date:  2020-12-25

6.  M148R and M149R are two virulence factors for myxoma virus pathogenesis in the European rabbit.

Authors:  Sophie Blanié; Jérémy Mortier; Maxence Delverdier; Stéphane Bertagnoli; Christelle Camus-Bouclainville
Journal:  Vet Res       Date:  2008-11-19       Impact factor: 3.683

7.  Myxoma virus therapy for human embryonal rhabdomyosarcoma in a nude mouse model.

Authors:  Veronica G Kinn; Valerie A Hilgenberg; Amy L MacNeill
Journal:  Oncolytic Virother       Date:  2016-08-08

Review 8.  On the potential of oncolytic virotherapy for the treatment of canine cancers.

Authors:  Amy L MacNeill
Journal:  Oncolytic Virother       Date:  2015-08-26

9.  Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib.

Authors:  Laura V Ashton; Barbara Graham; Maryam F Afzali; Daniel Gustafson; Amy L MacNeill
Journal:  Oncolytic Virother       Date:  2020-05-26

10.  Recombinant Myxoma Virus Expressing Walleye Dermal Sarcoma Virus orfC Is Attenuated in Rabbits.

Authors:  Laura V Ashton; Sandra L Quackenbush; Jake Castle; Garin Wilson; Jasmine McCoy; Mariah Jordan; Amy L MacNeill
Journal:  Viruses       Date:  2020-05-08       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.